In this issue of PET Clinics, guest editors Drs. Harshad Kulkarni and Abass Alavi bring their considerable expertise to the topic of Theranostics. Tops experts cover key topics such as total-body PET in theranostics: transforming treatment planning and follow-up; FAP-targeted imaging and therapy; theranostics in neuroendocrine neoplasms: integrating imaging, therapy, and dosimetry; theranostics: when targeting imaging leads to a targeted therapy; and much more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. CME Accreditation Page - p. xi 8. Preface - p. xiii 9. Theranostics in Nuclear Medicine: Historical, Regulatory, and Evidence Context for the Practicing Nuclear Medicine Physician - p. 331 10. Total-Body PET in Theranostics: Reshaping Treatment Planning and Follow-Up - p. 343 11. State-of-the-Art Theranostics of Thyroid Cancer - p. 353 12. Theranostics in Neuroendocrine Neoplasms: The Multifaceted Aspects Integrating Imaging, Therapy, and Dosimetry - p. 363 13. Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards - p. 383 14. Artificial Intelligence Across the PSMA Theranostic Continuum in Prostate Cancer - p. 393 15. Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen - p. 403 16. Fibroblast Activation Protein: Molecular Imaging and Beyond - p. 415 17. Theranostics: When Targeted Imaging Guides Targeted Therapy - p. 423 18. Role of PET in Radiation Oncology: A Theranostic Perspective on Detection of Radiation-Induced Complications - p. 435 19. Building Sustainable Theranostics Programs: Operational Models, Access, and Equity - p. 447
In this issue of PET Clinics, guest editors Drs. Harshad Kulkarni and Abass Alavi bring their considerable expertise to the topic of Theranostics. Tops experts cover key topics such as total-body PET in theranostics: transforming treatment planning and follow-up; FAP-targeted imaging and therapy; theranostics in neuroendocrine neoplasms: integrating imaging, therapy, and dosimetry; theranostics: when targeting imaging leads to a targeted therapy; and much more.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. CME Accreditation Page - p. xi 8. Preface - p. xiii 9. Theranostics in Nuclear Medicine: Historical, Regulatory, and Evidence Context for the Practicing Nuclear Medicine Physician - p. 331 10. Total-Body PET in Theranostics: Reshaping Treatment Planning and Follow-Up - p. 343 11. State-of-the-Art Theranostics of Thyroid Cancer - p. 353 12. Theranostics in Neuroendocrine Neoplasms: The Multifaceted Aspects Integrating Imaging, Therapy, and Dosimetry - p. 363 13. Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer – Current State and Evolving Standards - p. 383 14. Artificial Intelligence Across the PSMA Theranostic Continuum in Prostate Cancer - p. 393 15. Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen - p. 403 16. Fibroblast Activation Protein: Molecular Imaging and Beyond - p. 415 17. Theranostics: When Targeted Imaging Guides Targeted Therapy - p. 423 18. Role of PET in Radiation Oncology: A Theranostic Perspective on Detection of Radiation-Induced Complications - p. 435 19. Building Sustainable Theranostics Programs: Operational Models, Access, and Equity - p. 447
